These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 17611020)

  • 21. The neuroblastoma amplified gene, NAG: genomic structure and characterisation of the 7.3 kb transcript predominantly expressed in neuroblastoma.
    Scott DK; Board JR; Lu X; Pearson AD; Kenyon RM; Lunec J
    Gene; 2003 Mar; 307():1-11. PubMed ID: 12706883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group.
    George RE; Kenyon RM; McGuckin AG; Malcolm AJ; Pearson AD; Lunec J
    Oncogene; 1996 Apr; 12(7):1583-7. PubMed ID: 8622876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of candidate gene co-amplification with MYCN in neuroblastoma.
    George RE; Kenyon R; McGuckin AG; Kohl N; Kogner P; Christiansen H; Pearson AD; Lunec J
    Eur J Cancer; 1997 Oct; 33(12):2037-42. PubMed ID: 9516849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
    Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
    Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
    Wang M; Zhou C; Cai R; Li Y; Gong L
    Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of two dead box genes (DDX1 and DDX6) is independent of that of MYCN in human neuroblastoma cell lines.
    Akiyama K; Akao Y; Yokoyama M; Nakagawa Y; Noguchi T; Yagi K; Nishi Y
    Biochem Mol Biol Int; 1999 Apr; 47(4):563-8. PubMed ID: 10319407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of germline DDX1-MYCN duplication in inherited nephroblastoma.
    Fievet A; Belaud-Rotureau MA; Dugay F; Abadie C; Henry C; Taque S; Andrieux J; Guyetant S; Robert M; Dubourg C; Edan C; Rioux-Leclercq N; Odent S; Jaillard S
    Eur J Med Genet; 2013 Dec; 56(12):643-7. PubMed ID: 24161495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis.
    Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C
    Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
    Weber A; Starke S; Bergmann E; Christiansen H
    Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gain of MYCN region in a Wilms tumor-derived xenotransplanted cell line.
    Noguera R; Villamón E; Berbegall A; Machado I; Giner F; Tadeo I; Navarro S; Llombart-Bosch A
    Diagn Mol Pathol; 2010 Mar; 19(1):33-9. PubMed ID: 20186010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes.
    Fix A; Lucchesi C; Ribeiro A; Lequin D; Pierron G; Schleiermacher G; Delattre O; Janoueix-Lerosey I
    Genes Chromosomes Cancer; 2008 Oct; 47(10):819-34. PubMed ID: 18553563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
    Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
    Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The MYCN enigma: significance of MYCN expression in neuroblastoma.
    Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
    Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
    Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
    Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
    Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
    J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
    Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
    Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
    Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y
    J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.